相似文献
1
Gold Therapy in Rheumatoid Arthritis: Final Report of a Multicentre Controlled Trial.类风湿关节炎的金疗法：一项多中心对照试验的最终报告。
Ann Rheum Dis. 1961 Dec;20(4):315-34. doi: 10.1136/ard.20.4.315.
2
GOLD therapy in rheumatoid arthritis. Report of a multicentre control trial.类风湿关节炎的金制剂治疗。一项多中心对照试验报告。
Ann Rheum Dis. 1960 Jun;19(2):95-119.
3
4
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.利妥昔单抗与托珠单抗治疗抗 TNF 应答不足的类风湿关节炎患者（R4RA）：分层、基于活检、多中心、开放标签、4 期随机对照临床试验的 16 周结果。
Lancet. 2021 Jan 23;397(10271):305-317. doi: 10.1016/S0140-6736(20)32341-2.
5
Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.
Lancet. 2020 Jul 25;396(10246):267-276. doi: 10.1016/S0140-6736(20)30636-X.
6
Proceedings: Penicillamine or gold for rheumatoid arthritis? Multicentre trial using 'blind' observers. The first six months.研究报告：青霉胺与金制剂治疗类风湿性关节炎的比较？采用“盲法”观察的多中心试验。头六个月
Ann Rheum Dis. 1974 Jul;33(4):399. doi: 10.1136/ard.33.4.399-a.
7
8
Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial.阿巴西普在类风湿关节炎高危个体中的应用（APIPPRA）：一项随机、双盲、多中心、平行、安慰剂对照、2b 期临床试验。
Lancet. 2024 Mar 2;403(10429):838-849. doi: 10.1016/S0140-6736(23)02649-1. Epub 2024 Feb 13.
9
Gait Rehabilitation for Early rheumatoid Arthritis Trial (GREAT): lessons learnt from a mixed-methods feasibility study and internal pilot trial.早期类风湿性关节炎步态康复试验（GREAT）：来自混合方法可行性研究和内部预试验的经验教训
Health Technol Assess. 2025 Mar 26:1-48. doi: 10.3310/XBDJ8546.
10
Does intensive management improve remission rates in patients with intermediate rheumatoid arthritis? (the TITRATE trial): study protocol for a randomised controlled trial.强化管理能否提高中度类风湿性关节炎患者的缓解率？（TITRATE试验）：一项随机对照试验的研究方案。
Trials. 2017 Dec 8;18(1):591. doi: 10.1186/s13063-017-2330-8.
引用本文的文献
1
To stop the erosion of hope: the DMARD category and the place of semantics in modern rheumatology.阻止希望的破灭：改善病情抗风湿药类别及语义学在现代风湿病学中的地位
Inflammopharmacology. 2017 Apr;25(2):185-190. doi: 10.1007/s10787-017-0320-9. Epub 2017 Feb 13.
2
Nanotechnologies for noninvasive measurement of drug release.用于药物释放无创测量的纳米技术。
Mol Pharm. 2014 Jan 6;11(1):24-39. doi: 10.1021/mp400419k. Epub 2013 Nov 26.
3
Inhibition of cathepsin B by Au(I) complexes: a kinetic and computational study.
J Biol Inorg Chem. 2008 May;13(4):555-61. doi: 10.1007/s00775-008-0344-0.
4
Measurement of global functional performance in patients with rheumatoid arthritis using rheumatology function tests.使用风湿病功能测试对类风湿性关节炎患者的整体功能表现进行测量。
Arthritis Res Ther. 2004;6(4):R315-25. doi: 10.1186/ar1188. Epub 2004 May 21.
5
A clinical and economic review of disease-modifying antirheumatic drugs.改善病情抗风湿药物的临床与经济学综述
Pharmacoeconomics. 2001;19(7):715-28. doi: 10.2165/00019053-200119070-00002.
6
Medical management of children with juvenile rheumatoid arthritis.青少年类风湿关节炎患儿的医学管理
Drugs. 1999 Nov;58(5):831-50. doi: 10.2165/00003495-199958050-00006.
7
Placebo effects. Placebos used not to be used in studies.安慰剂效应。过去在研究中不使用安慰剂。
BMJ. 1995 Dec 16;311(7020):1641. doi: 10.1136/bmj.311.7020.1641.
8
Randomized trial of switching rheumatoid arthritis patients in remission with injectable gold to auranofin.将注射用金制剂治疗处于缓解期的类风湿关节炎患者转换为使用金诺芬的随机试验。
Clin Rheumatol. 1994 Mar;13(1):60-9. doi: 10.1007/BF02229867.
9
Mechanisms of action of gold.金的作用机制。
Agents Actions. 1981 Nov;11(5):458-72. doi: 10.1007/BF02004707.
10
Antirheumatic drugs: clinical pharmacology and therapeutic use.抗风湿药物：临床药理学与治疗应用。
Drugs. 1980 Dec;20(6):453-84. doi: 10.2165/00003495-198020060-00002.
本文引用的文献
1
A controlled trial of phenylbutazone, oxyphenbutazone, and a placebo in the treatment of rheumatoid arthritis.
Ann Rheum Dis. 1961 Jun;20(2):161-72. doi: 10.1136/ard.20.2.161.
Zotero 插件